Celltech Group (NYSE: CLL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celltech Group (NYSE: CLL)

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: Tom Nealon who wrote ()	2/17/2000 11:53:00 PM
From: Tom Nealon	Read Replies (1) of 123

From the Financial Times: Target date Product Company Originator Indication Bioengineered vaccine 31/12/00 Hepagene Celltech Chiroscience Medeva Hepatitis B prophylaxis and Hepatitis B treatment 30/06/01 Arilvax Peptide Therapeutics Evans Medical Yellow fever prophylaxis 31/12/01 Malaria vaccine SmithKline Beecham SmithKline Beecham Malaria prophylaxis Monoclonal antibody 30/06/00 Bexxar SmithKline Beecham Coulter Pharmaceutical Non-Hodgkin's lymphoma 31/12/00 CDP 571 Celltech Chiroscience Celltech Rheumatoid arthritis and Crohn's disease Other biotechnology product 31/12/00 CMA 676 Celltech Chiroscience Celltech/American Acute myeloid leukaemia Home Products 31/12/02 CMB 401 Celltech Chiroscience Celltech/American Non-small cell lung cancer Home Products and Ovarian cancer Recombinant product 31/12/02 ZD 4927 AstraZeneca Zeneca Deep venous thrombosis Transgenic product 31/12/01 Alpha-1-antitrypsin PPL Therapeutics PPL Therapeutics AAT congenital deficiency and Cystic fibrosis 31/12/02 Fibrinogen PPL Therapeutics PPL Therapeutics "Haemophilia, general" 31/12/02 Bile Salt PPL Therapeutics PPL Therapeutics Digestive insufficiency Stimulated Lipase Source: Evaluate

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext